Brainsway
Hartom 19 str
Bynet Building, 5th Floor
Har Hachotzvim
Tel: 972-2-5813140
Fax: 972-2-5812517
Website: http://www.brainsway.com/
Email: info@brainsway.com
147 articles about Brainsway
-
BrainsWay Reports Open Market Stock Purchases by Two Board Members
11/28/2022
BrainsWay Ltd. today reported that David Zacut, M.D., BrainsWay’s Chairman of the Board of Directors, and Avner Hagai, an independent Director on BrainsWay’s Board, separately purchased BrainsWay ordinary shares in recent open market purchases.
-
BrainsWay Reports Third Quarter 2022 Financial Results and Operational Highlights
11/16/2022
BrainsWay Ltd. today reported third quarter 2022 financial results and provided an operational update.
-
The executive shuffle continues across the biopharma industry as companies shore up leadership needs with these Movers & Shakers.
-
BrainsWay Announces Private Insurance Coverage from Premera Blue Cross for the Treatment of OCD Utilizing Deep TMS™
11/3/2022
BrainsWay Ltd. announced that Premera Blue Cross, an independent licensee of the Blue Cross Blue Shield Association, will extend positive coverage applicable to Deep Transcranial Magnetic Stimulation for the treatment of obsessive-compulsive disorder as of February 3, 2023.
-
BrainsWay to Report Third Quarter Financial Results on November 16, 2022
11/2/2022
BrainsWay Ltd. announced that it will report its third quarter financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 16, 2022.
-
BrainsWay Appoints Dr. Colleen A. Hanlon as Vice President of Medical Affairs
11/1/2022
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced the appointment of Colleen A. Hanlon, Ph.D. as Vice President of Medical Affairs.
-
BrainsWay CEO Christopher von Jako Named Honorary Chair of NAMIWalks Silicon Valley
9/20/2022
BrainsWay Ltd., a world leader in advanced and noninvasive treatment for brain disorders, announced that its President and CEO, Christopher von Jako, PhD, was named an honorary cochair of NAMIWalks Silicon Valley.
-
BrainsWay Announces Significant Private Insurance Coverage from Cigna Corporation for the Treatment of OCD Utilizing Deep TMS™
9/14/2022
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced that Cigna Corporation has announced positive coverage applicable to Deep Transcranial Magnetic Stimulation for the treatment of obsessive-compulsive disorder.
-
The U.S. Food and Drug Administration had a busy week leading up to the Labor Day holiday. Here’s a look at the agency’s recent activities.
-
Global Roundup: Clover Progresses Universal COVID-19 Booster, TikoMed Proves Platform in ALS
9/1/2022
Clover's SCB-2019 showed a robust immune response to the Omicron BA.5 sub-variant, while BrainsWay, TikoMed and more provide updates on their businesses and pipelines. -
BrainsWay to Present at the H.C. Wainwright Annual Global Investment Conference in September 2022
8/31/2022
BrainsWay Ltd., a global leader in advanced and non-invasive treatment for brain disorders, announced that Christopher von Jako, Ph.D., President and Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Annual Global Investment Conference being held at the Lotte Palace Hotel in New York City on September 12-14, 2022.
-
BrainsWay Receives New FDA Clearance for Treating Depression and Anxious DepressionDepression Clearance for the Proprietary Deep TMS™ H7 Coil Represents the Company’s 9th FDA Clearance
8/29/2022
BrainsWay Ltd. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Deep TMS™ H7 Coil for its use in treating adults suffering from major depressive disorder and depression.
-
BrainsWay Reports Second Quarter 2022 Financial Results and Operational Highlights
8/10/2022
BrainsWay Ltd. today reported second quarter 2022 financial results and provided an operational update.
-
BrainsWay to Report Second Quarter Financial Results on August 10, 2022
7/27/2022
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its second quarter financial results and operational highlights before the open of the U.S. financial markets on Wednesday, August 10, 2022.
-
BrainsWay Announces Insurance Coverage by Israeli Ministry of Health for the Treatment of Depression
6/28/2022
BrainsWay Ltd. announced that, for the first time, the Israeli Ministry of Health has approved coverage applicable to its Deep TMS™ system for the treatment of depression.
-
BrainsWay to Present at the H.C. Wainwright 1st Annual Mental Health Conference
6/22/2022
BrainsWay Ltd. announced that Christopher von Jako, PhD, BrainsWay’s President, and Chief Executive Officer, will participate in a fireside chat and panel discussion at the H.C. Wainwright 1st Annual Mental Health Conference being held at the Lotte New York Palace Hotel on June 27, 2022.
-
BrainsWay Announces Positive OCD Coverage Policy from Blue Cross Blue Shield® (BCBS) Licensee Highmark BCBS for Deep TMS™
6/21/2022
BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced that Highmark Blue Cross Blue Shield has issued a positive coverage policy applicable to the BrainsWay Deep TMS™ system for the treatment of obsessive-compulsive disorder, effective May 2, 2022.
-
BrainsWay Reports First Quarter 2022 Financial Results and Operational Highlights
5/11/2022
BrainsWay Ltd. a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported first quarter 2022 financial results and provided an operational update.
-
BrainsWay to Report First Quarter Financial Results on May 11, 2022
4/27/2022
BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will report its first quarter financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 11, 2022.
-
BioSpace Movers & Shakers, April 1
4/1/2022
It's a new month and a new chapter for several life sciences executives. Here's a look at some notable Movers & Shakers beginning April with new companies.